The role of osteopontin: A shared pathway in the pathogenesis of multiple sclerosis and osteoporosis?

Journal of the Neurological Sciences

Volumn 276, Issue 1-2, 2009, Pages 41-44

  Altintaş, Ayse ^a   Saruhan Direskeneli, Guher ^b   Benbir, Gulcin ^a   Demir, Mustafa ^a   Purisa, Sevim ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bone mineral density; Multiple sclerosis; Osteopontin

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; OSTEOPONTIN;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FEMUR NECK; HUMAN; MALE; MULTIPLE SCLEROSIS; ONSET AGE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SEX DIFFERENCE; STEROID THERAPY;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BONE DENSITY; CASE-CONTROL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPONTIN; OSTEOPOROSIS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 58149174185     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.08.031     Document Type: Article

References (35)

1. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Navarro J.B., et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158 (2005) 231-239
2. Kantarci O.H., de Andrade M., and Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123 (2002) 144-159
3. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol 136 (2003) 125-129
4. Liaw L., Skinner M.P., Raines E.W., Ross R., Cheresh D.A., and Schwartz S.M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95 (1995) 713-724
5. Choi J.S., Park H.J., Cha J.H., Chung J.W., Chun M.H., and Lee M.L. Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol 141 (2007) 74-83
6. Choi JS, Park HJ, Cha JH, Chung JW, Chun MH, Lee MY., Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol 2003: 141:65-73.
7. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunol 2 (2001) 762-764
8. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 (1996) 299-302
9. Blom T., Franzen A., Heinegard D., and Holmdahl R. Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease". Science 299 (2003) 1845
10. Abel B., Kurrer M., Shamshiev A., Marty R.R., Ericksson U., and Günthert U. The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur J Immunol 36 (2006) 494-499
11. Hensiek A.E., Roxburg R., Merenian M., Seaman S., Yeo T., and Compston D.A. Osteopontin gene and clinical severity of multiple sclerosis. J Neurol 25 (2003) 943-947
12. Caillier S., Barcellos L.F., Baranzini S.E., Swerdlin A., Lincoln R.R., Steinman L., et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun 4 (2003) 312-315
13. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C.A., Rittling S.R., Denhardt D.T., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
14. Jansson M., Panoutsakopoulou V., Baker J., Klein L., and Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168 (2002) 2096-2099
15. Denhardt D.T., and Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem 31 (1998) 92-102
16. Young M.F., Kerr J.M., Termine J.D., Wewer U.M., Wang M.G., and McBride O.W. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7 (1990) 491-502
17. Ishijima M., Ezura Y., Tsuji K., Rittling S.R., Kurosawa H., and Denhardt D.T. Osteopontin is associated with nuclear factor κB gene expression during tail-suspension-induced bone loss. Exp Cell Res 312 (2006) 3075-3083
18. Gravallase E.M. Osteopontin: a bridge between bone and the immune system. J Clin Invest 112 2 (Jul 2003) 147-149
19. Tuzun S., Altintas A., Karacan I., Tangu S., Saip S., and Siva A. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 9 (2003) 600-604
20. Navikas V., and Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45 (1996) 322-333
21. Vogt M.H.J., Lopatinskaya L., Smits M., Polman C.H., and Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 53 (2003) 819-822
22. Duran I., Martinez-Caceres E.M., Rio J., Barbera N., Marzo M.E., and Montalban X. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122 (1999) 2297-2307
23. McDonnell G.V., McMillan S.A., Douglas J.P., Droogan A.G., and Hawkins S.A. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. J Neurol 246 (1999) 87-92
24. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson A.J., et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 48 (1997) 1557-1565
25. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassman H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47 (2000) 707-717
26. Vogt M.H.J., Floris S., Killestein J., Knol D.L., Smits M., and Barkhof C.H. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155 (2004) 155-160
27. Cosman F., Nieves I., and Komar L. Fracture history and bone loss in patients with MS. Neurology 51 (1998) 1161-1165
28. Nieves J., Cosman F., Herbert J., Shen V., and Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44 (1994) 1687-1692
29. Schwid S.R., Goodman A.D., Puzas E., McDermott M.P., and Matson D.H. Sporadic glucocorticoid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53 (1996) 753-757
30. Formica C.A., Cosman F., Nieves J., Herbert J., and Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61 (1997) 129-133
31. Lucas K., and Hohfeld R. Differential aspects of cytokines in the immunopathology of MS. Neurology 45 (1995) 4-5
32. Rifas L. Bone and cytokines: beyond IL-1, 11-6 and TNF-a. Calcif Tissue Int 64 (1999) 1-7
33. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J 7 (1993) 1475-1482
34. Patarca R., Saavedra R.A., and Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13 (1993) 225-246
35. Chiocchetti A., Comi C., Indelicato M., Castelli L., Mesturini R., Bensi T., Mazzarino M.C., et al. Osteopontin gene halotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 163 (2005) 172-178